• Center on Health Equity & Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

Dr Steve Miller Weighs Pros and Cons of Medicare Part B Proposal

Video

The new Medicare Part B proposal from CMS has been controversial, and Steve Miller, MD, senior vice president and chief medical officer of Express Scripts, understands both sides of the argument. While he appreciates CMS' dedication to innovation, the demonstration may drive up payer costs.

The new Medicare Part B proposal from CMS has been controversial, and Steve Miller, MD, senior vice president and chief medical officer of Express Scripts, understands both sides of the argument. While he appreciates CMS' dedication to innovation, the demonstration may drive up payer costs.

Transcript (slightly modified)

What is your take on the Medicare Part B demonstration proposed by CMS?

So we actually think there’s both good and bad in what they’ve proposed. The good is that CMS really wants to innovate, and as you know many of the regulations make it hard to innovate, and so they’re really listening closely and very excited to experiment. We think that that change in reimbursement for the physicians may actually have a deleterious effect. That is, if we drive more physicians into big medical centers where those drugs are actually paid for by the medical centers at a higher rate, that that also the use of the 340B, that’s what’s going to happen is they’ll have fewer doctors practicing in private practice. It would be a little more inconvenient for patients, but it may be a lot more expensive for payers.

Related Videos
Coral Omene, MD, PhD, sitting for a vieo interview
Dr Ola Landgren
David Awad, PharmD, BCOP
Gordon Crofoot, MD, PA
Jaime Almandoz, MD, MBA
Screenshot of Coral Omene, MD, PhD
Dr Brian Slomovitz
H. John Beardsley, MBA, and Fauzea Hussain, MPH, sitting for a video interview
Adam Colborn, JD, associate vice president for congressional affairs, Academy of Managed Care Pharmacy (AMCP)
ASCO 2025
Related Content
© 2025 MJH Life Sciences
AJMC®
All rights reserved.